Stock VNDA VANDA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		5-day change 1st Jan Change
5.13 USD +1.58% Intraday chart for Vanda Pharmaceuticals Inc. -6.39% +21.56%
05-08 Transcript : Vanda Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024
05-08 Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vanda: Q1 Earnings Snapshot
AQ
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
PR
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
PR
Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
PR
Vanda Strikes Out At The Supreme Court
AQ
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
AQ
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ ANDA Litigation
AQ
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
PR
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
PR
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
PR
VANDA Pharmaceuticals States A Fifth Amendment Claim Against The Government For Taking A Trade Secret
AQ
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
PR
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
PR
Does Government Disclosure Of A Company's Trade Secrets Amount To An Unlawful Taking Under The Fifth Amendment?
AQ
Vanda: Q4 Earnings Snapshot
AQ
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
PR
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. News Vanda Pharmaceuticals Inc.
  5. Press Releases